Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chronix Biomedical has opened a fully operational sequencing laboratory in Brookings, South Dakota, US, to expand its commercial capabilities.
Subscribe to our email newsletter
Chronix has opened the laboratory in association with the First Bank & Trust of Brookings, South Dakota and the Area Development Corporation of Brookings, South Dakota.
The Brookings laboratory will offer sequencing services to academic and pharmaceutical researchers who wish to support their biomarker programs in diseases that are considered "orphan" or for which there is no diagnostic test currently available, said the company.
Chronix currently is providing sequencing services to clinicians, universities, industry and government agencies for breast cancer, prostate cancer, colorectal cancer, brain injuries and concussions, bovine spongiform encephalopathy (mad cow disease) and Chronic Fatigue Syndrome.
Chronix Biomedical CEO Howard Urnovitz said next generation sequencing is the game changing technology the company needs to provide next generation healthcare.
"Our proprietary approach to identifying previously unknown and undetected biomarkers is an important new application that detects active disease as opposed to detecting the risk of disease. The technology is so powerful that these biomarkers focus on each individual’s unique changes," Urnovitz said.
Finance and Administration senior vice-president John DiPietro said, "We anticipate that the success of this first specialty laboratory in Brookings will enable us to launch additional satellite sequencing facilities in collaboration with major research cancer centers around the country."